Diabetes and cancer

Andersen, Dana K.

doi:10.1097/med.0b013e32835eddd3

Cited by 28 publications

(13 citation statements)

References 48 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings imply that the increasing incidence of pancreatic cancer 2 might be attributed to the rapid increase in prediabetes/diabetes, a global epidemic affecting 14.2% (629 million) of the world’s adult population. 16 48 Furthermore, prediabetes could provide an important opportunity for prevention of pancreatic cancer, the most effective strategy to reduce related mortality 4 5 given that pancreatic cancer evades early detection and responds poorly to treatment. 1 Prediabetes precedes overt type 2 diabetes and can be improved or even reversed through changes in lifestyle.…”

Section: Discussionmentioning

confidence: 99%

“… 1 2 3 As about 85% of the tumors are already unresectable at diagnosis, 1 prevention through modification of its risk factors is especially important. 4 5 Epidemiological evidence supports type 2 diabetes as a risk factor for pancreatic cancer, 4 6 and chronic hyperinsulinaemia and hyperglycaemia associated with type 2 diabetes have been proposed as the underlying mechanism. Experimental evidence suggests that insulin promotes proliferation and reduces apoptosis in pancreatic cancer cells, both directly and indirectly through increased bioavailability of insulin-like growth factor 1.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis

Liao

et al. 2015

BMJ

133

View full text Add to dashboard Cite

Objective To evaluate potential linear and non-linear dose-response relations between blood glucose and risk of pancreatic cancer.Design Systematic review and dose-response meta-analysis of prospective observational studies.Data sources Search of PubMed, Scopus, and related reviews before 30 November 2013 without language restriction.Eligibility criteria Prospective studies evaluating the association between blood glucose concentration and pancreatic cancer. Retrospective and cross sectional studies excluded to avoid reverse causality.Data extraction and synthesis Two reviewers independently extracted relevant information and assessed study quality with the Newcastle-Ottawa scale. Random effects dose-response meta-analysis was conducted to assess potential linear and non-linear dose-response relations.Results Nine studies were included for analysis, with a total of 2408 patients with pancreatic cancer. There was a strong linear dose-response association between fasting blood glucose concentration and the rate of pancreatic cancer across the range of prediabetes and diabetes. No non-linear association was detected. The pooled rate ratio of pancreatic cancer per 0.56 mmol/L (10 mg/dL) increase in fasting blood glucose was 1.14 (95% confidence interval 1.06 to 1.22; P<0.001) without significant heterogeneity. Sensitivity analysis excluding blood glucose categories in the range of diabetes showed similar results (pooled rate ratio per 0.56 mmol/L increase in fasting blood glucose was 1.15, 95% confidence interval 1.05 to 1.27; P=0.003), strengthening the association between prediabetes and pancreatic cancer.Conclusions Every 0.56 mmol/L increase in fasting blood glucose is associated with a 14% increase in the rate of pancreatic cancer. As prediabetes can be improved or even reversed through lifestyle changes, early detection of prediabetes coupled with lifestyle changes could represent a viable strategy to curb the increasing incidence of pancreatic cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis

Liao

et al. 2015

BMJ

133

View full text Add to dashboard Cite

show abstract

“…Moreover, within 10 years, the relative risk was still increased, with a relative risk of 1.36 [3]. Around 75% of pancreatic adenocarcinoma patients have T2DM at the time of diagnosis, which indicates a strong association between T2DM and pancreatic adenocarcinoma [4]. The relationship between diabetes mellitus and pancreatic adenocarcinoma remains unclear regarding the type of diabetes associated with pancreatic adenocarcinoma.…”

Section: Introductionmentioning

confidence: 99%

“…T2DM, found in most elderly people, is the dominant risk factor for pancreatic adenocarcinoma with a prevalence of 80%-90% in most cases [ 5 ]. As the incidence of pancreatic adenocarcinoma, along with mortality, increased, the association has obtained more and more significance [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Pancreatic Adenocarcinoma in Patients with Type 2 Diabetes: Prognosis and Survival

Turjoman

Alshaikh

Althobaiti

et al. 2020

Cureus

View full text Add to dashboard Cite

Introduction Pancreatic adenocarcinoma and type 2 diabetes mellitus (T2DM) are interrelated. The outcomes of this association were the topic of interest of a lot of prior research in this field. The primary objective of this research is the identification of the survival rate and mortality difference between patients with pancreatic adenocarcinoma and T2DM and those without. Methods A retrospective observational study included 83 patients who were diagnosed and managed between 2005 and 2015 at Princess Noorah Oncology Center, King Abdulaziz Medical City, Jeddah. Patients with T2DM who were older than 18 years old and were diagnosed later with pancreatic adenocarcinoma were included. Results Out of 83 patients with pancreatic adenocarcinoma, 86.75% (n=72) had T2DM at the time of diagnosis. The median age at diagnosis was significantly higher than in patients without T2DM (p=0.003). The overall survival was not affected by T2DM (p=0.289). However, hypertension had a significant impact on survival rate regardless of the presence of T2DM (OR, 3.47 (95% CI: 1.09-10.98)). Conclusion Patients with pancreatic adenocarcinoma and T2DM were mostly women and aged around 60. T2DM did not have a significant effect on tumor profile. T2DM did not significantly affect survival, although other comorbidities, such as hypertension, did.

show abstract

“…[ 17 ] The normalization of glucose level is particularly important in case of pancreatic cancer that is closely associated with diabetes mellitus (DM). [ 18 – 21 ] Furthermore, thanks to the development of analytic tool for imaging data, interrelations of individual pixels can be interrogated in a mathematical way, generating the unique texture pattern of given imaging data (=texture analysis). This kind of texture analysis firstly has been applied to the high resolution images such as histopathology or magnetic resonance imaging [ 22 ] and being expanded to nuclear imaging data such as PET.…”

Section: Introductionmentioning

confidence: 99%

Prognosis prediction of pancreatic cancer after curative intent surgery using imaging parameters derived from F-18 fluorodeoxyglucose positron emission tomography/computed tomography

et al. 2020

View full text Add to dashboard Cite

show abstract

Diabetes and cancer

Abstract: The death rate because of pancreatic and other cancers can be reduced by an aggressive approach to reversing obesity and hyperinsulinemia, achieving good glycemic control in diabetic patients, and identifying at an early timepoint those patients with pancreatogenic diabetes.

Cited by 28 publications

References 48 publications

Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis

Blood glucose concentration and risk of pancreatic cancer: systematic review and dose-response meta-analysis

Pancreatic Adenocarcinoma in Patients with Type 2 Diabetes: Prognosis and Survival

Prognosis prediction of pancreatic cancer after curative intent surgery using imaging parameters derived from F-18 fluorodeoxyglucose positron emission tomography/computed tomography

Contact Info

Product

Resources

About